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The emergence of opportunistic Acinetobacter spp. in healthcare settings poses
a signiﬁcant threat to public health. The major reasons for nosocomial spread of these
species are their abilities to develop and transfer drug resistance against various classes
of antibiotics. Considering that Acinetobacter spp. are ubiquitous in nature, can utilize
several carbon sources, and reach humans via various pathways, our aim was to obtain
information about the environmental strains of this genus. Our ﬁrst step was to develop
and test a multistep isolation procedure based on traditional scientiﬁc methods.
Antibiotic resistance patterns of the isolated strains were determined, as susceptibility
to 12 antibiotics of 7 classes was tested by MIC Test Strip method. Altogether 366
samples (groundwater, surface water, and soil) of 24 sites were investigated and a
collection of 37 Acinetobacter isolates was obtained. Among others, clinically
important human pathogen Acinetobacter spp., such as A. baumannii, A. johnsonii,
and A. gyllenbergii were identiﬁed. Three environmental strains were determined as
multidrug-resistant including a carbapenem-resistant, hemolytic Acinetobacter beijer-
inckii strain isolated from a hydrocarbon-contaminated groundwater sample. In
summary, it has been found that the applied multistep isolation procedure is applicable
to isolate various species of Acinetobacter genus. Based on the antibiotic resistance
assay, we can conclude that environmental representatives of Acinetobacter spp. are
able to develop multidrug resistance, but at a lower rate than their clinical counterparts.
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Introduction
The necessity of simultaneous investigations of environmental and clinical
isolates of opportunistic species is a rising issue in our days, since pathways
between clinical and non-clinical environments are both globally and locally
opening. In the case of some clinically important species such as Pseudomonas
aeruginosa, comparative studies are available regarding virulence factors, geno-
mic diversity [1], or antibiotic resistance of strains isolated from various environ-
mental sources. However, Acinetobacter strains of clinical and environmental
habitats are still considered and examined in various ways.
Acinetobacter species are ubiquitous in natural habitats (soil and water).
Their presence was veriﬁed in the normal skin, throat, and rectal ﬂora as well as
in food and body lice [2]. The representatives of this genus can cause serious
respiratory, urinary, and biliary tract infections; empyema; bacteremia; menin-
gitis; endocarditis; burn infections; and wound sepsis [3, 4]. Acinetobacter
strains related to nosocomial infections are mainly found in intensive care units
and in burns or high dependency units treating severely ill or debilitated patients
[5]. In addition, infections caused by Acinetobacter baumannii have been
reported in the case of military personnel of combat regions such as Afghanistan
or Iraq [6].
Among all Acinetobacter species, the Acinetobacter calcoaceticus–
baumannii complex (ACB) has the greatest inﬂuence on clinical healthcare;
therefore, ACB is the critical subject of the current scientiﬁc investigations. The
members of the ACB complex (A. baumannii, A. calcoaceticus, Acinetobacter
pittii, and Acinetobacter nosocomialis) are in close phylogenetic relation; there-
fore, their differentiation solely on phenotypic characterization is difﬁcult [7, 8].
Acinetobacter-related infections can pose serious clinical concerns with high
mortality of patients. Due to the high rate of multidrug-resistant (MDR)
Acinetobacter strains in clinical settings [9], some Acinetobacter species such
as A. baumannii are mentioned as “emerging nosocomial superbugs” [10].
Regarding antibiotic resistance features, the emergence of MDR
Acinetobacter strains has been reported from hospital settings all over the
world, and the number of infections caused by these strains is continuously
increasing [2, 5]. The treatment of MDR Acinetobacter strains is complicated
because (due to the production of OXA-type carbapenemases) the majority of
clinical Acinetobacter spp. is resistant to carbapenems, a commonly used group
of ﬁrst-line antimicrobial agents [11]. Moreover, some A. baumannii strains were
reported to be resistant to all available antibiotics [12], due to their great set of
various antibiotic resistance mechanisms, which lead to the emergence of
untreatable infections.
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Although clinical Acinetobacter spp. are well characterized, the available
information regarding antibiotic resistance patterns of Acinetobacter strains from
environmental samples is much limited and controversial, despite the recognition
of environment as a potential reservoir for Acinetobacter spp.-resistant isolates
[13]. The major reason for this is possibly the difﬁcult isolation and identiﬁcation
of ACB from environmental samples. Upon the information of scientiﬁc literature,
the existing methods for the isolation of Acinetobacter spp. are moderately
effective and are not standardized.
The available procedures for identiﬁcation are also limited and occasionally
are not veriﬁed by molecular genetic methods [13]. Recent publications about
Acinetobacter species used only classical microbiological methods or mass
spectrometry [10, 14] for identiﬁcation; however, none of these research works
used the reliable 16S rRNA-based molecular method for identiﬁcation.
Despite the clinical concerns of acinetobacters, some Acinetobacter strains
are considered as industrially important [15] due to their ability to degrade several
pollutants or industrial products [16–18] such as diesel oil [19]. However, the
clinically important features of these strains such as antibiotic resistance or
virulence are barely described.
Only a few scientiﬁc articles have discussed the antibiotic resistance of
environmental Acinetobacter strains. Dhakephalkar and Chopade [20] examined
different environmental sources (soil, river water, domestic sewage, treated
industrial efﬂuent, and laboratory efﬂuent) to isolate Acinetobacter strains and to
determine their antibiotic and metal resistance. Berlau et al. [21] isolated
Acinetobacter strains from vegetables and fruits to determine minimum inhibitory
concentrations (MICs) of six antimicrobial agents.
Based on the overview of the available scientiﬁc information on environ-
mental acinetobacters, our aim was to widen our knowledge on antibiotic/
multidrug resistance of naturally occurring Acinetobacter isolates, which can be
a possible source of non-nosocomial infections [22]. To reach our main objective,
we aimed to establish a culture collection of environmental Acinetobacter strains
and to determine their antibiotic resistance proﬁles.
Material and Methods
Environmental sample collection
Sampling period was between 2008 and 2013. Environmental samples were
taken in accordance with the relevant Hungarian standards MSZ 21464: 1998 [23]
and MSZ 12750/2-71: 1971 [24]. Altogether 366 samples of 24 Hungarian sites
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were collected for further examinations. Samples with a detectable number of
Acinetobacter strains (Table I) were originated from hydrocarbon-contaminated
and non-contaminated environments as follows:
• Groundwater: 15 samples with total petroleum hydrocarbons (TPH; Duna-
varsány, Füzesabony, Polgár, Siklo´s, Tiszaújváros, Vác, and Zalaegerszeg),
1 sample with methyl tert-butyl ether (MTBE; Marcali) contamination, and
10 non-contaminated samples (Bugyi, Siklo´s, and Vác);
• Soil: two samples with polycyclic aromatic hydrocarbons (PAHs; Pétfürdo˝);
• Surface water: six samples from non-contaminated ﬁshpond with no direct
use of antibiotics (Ho˝gyész, Kölesd, and Varsád).
Isolation of Acinetobacter species
Successful isolation of Acinetobacter strains was carried out based on
classical microbiological methods described in scientiﬁc literature. The recom-
mended media were examined with two Acinetobacter strains (Acinetobacter
beijerinckii and Acinetobacter johnsonii) formerly isolated in our department. The
colony morphology of Acinetobacter spp. was examined in cetrimide agar,
tryptone glucose yeast (TGY) agar, nutrient agar, McConkey agar [18] and Leeds
Acinetobacter Medium [25, 26] with different incubation parameters (28, 30, and
42 °C). Furthermore, Acinetobacter sp. enrichment liquid medium [27] was tested
in combination with TGY and Leeds Acinetobacter Medium agar.
Based on these preliminary investigations, the following protocol was imple-
mented in the case of environmental samples: each incoming sample was diluted in
tenfold series with physiological saline solution (101–104) and 1–1 ml of diluted
samples were inoculated into tubes containing Acinetobacter sp. enrichment liquid
medium (9 ml) [27]. After 48 h of incubation (28–30 °C and 160 rpm) agarized
Leeds AcinetobacterMedium [25] plates were poured containing 1 ml of the shaken
enriched cultures. After another incubation period of 72 h, colonies resemble
Acinetobacter spp. (mauve, round, intact edge, and shiny) on the surface of agar
plates were puriﬁed using streak plate method and subsequently inoculated onto
nutrient agar slants (MERCK 105450) for conservation and further investigations.
Identiﬁcation of strains
Before 16S rRNA gene base identiﬁcation, pure cultures of Acinetobacter
candidates were examined with oxidase and catalase tests [28]. Strains with
oxidase-negative and catalase-positive proﬁles were used for further examinations
(16S rRNA gene sequencing and antibiotic resistance investigations).
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16S rRNA gene-based identiﬁcation of strains
Acinetobacter candidates were identiﬁed based on 16S rRNA gene sequence
analysis. The 16S rRNA gene was ampliﬁed from chromosomal DNA. DNA of
strains from liquid cultures (24 h) was extracted and puriﬁed using the MOBIO
Ultra Clean Microbial DNA Isolation Kit (MOBIO Laboratories, USA) following
the manufacturer’s instructions, detected by 1% agarose gel electrophoresis and
visualized under ultraviolet light.
For ampliﬁcation of 16S rRNA genes, universal 27f (5′ GAG TTG ATC
CTG GTC AG 3′) forward and 1492r (5′ TAC GGG TAC CTT GTT ACG ACT T
3′) reverse primers were used [29]. The reaction parameters were as follows:
98 °C for 5 s, 32 cycles of 94 °C for 30 s, 52 °C for 30 s, 72 °C for 45 s, and
then a ﬁnal extension at 72 °C for 10 min. PCR reactions were performed in 50 μl
reaction volumes containing 5 μl Taq-Buffer (Fermentas, Lithuania), 10 μl (1 mM)
dNTP, 0.25 μl Taq DNA polymerase, 0.5 μl (1 μM) forward primer (27f), 0.5 μl
(1 μM) reverse primer (1492r), 1 μl DNA template, and 32.75 μl nuclease-free
water. Amplicons were detected by agarose gel electrophoresis, puriﬁed by
NucleoSpin Extract II DNA Clean-up set (Macherey-Nagel, Germany) and used
as a template for sequencing reactions using 27f as sequencing primer. The
nucleotide sequence determination was performed using the Big Dye Terminator
version 3.1 (Applied Biosystems, USA). Cycle Sequencing Kit (Applied Biosys-
tems) and sequences were analyzed using ABI 3130 Genetic Analyzer (Applied
Biosystems). Prior capillary gel electrophoresis products of the sequencing reactions
had been puriﬁed using ethanol precipitation method. The obtained sequences were
edited and assembled using MEGA5 software [30], and then homology BLAST
searches [31] were performed in the GenBank database. The determination of
closest type strain was carried out by EzTaxon-e server [32, 33]. Species-level
identiﬁcation was accepted above 98% sequence homology. Sequencing data
obtained in this study were submitted to the European Nucleotide Archive database
and can be found under accession numbers HG810368–HG810404.
Antibiotic resistance examination of environmental strains
The antibiotic sensitivity tests of environmental Acinetobacter strains were
performed according to the guidelines of the Clinical and Laboratory Standards
Institute (CLSI) [34].
For the determination of MIC values, MIC Test Strip (Lioﬁlchem, Italy) was
applied with 12 antibacterial agents belonging to 7 antibiotic groups (Table II). In
the ﬁrst step, bacterial suspensions of 0.5 McFarland value [35] were spread onto
the surface of Mueller–Hinton agar (MERCK 1.05435.0500) in accordance with
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the recommendation of the manufacturer. MIC Test Strips were positioned on the
surface of the inoculated medium. Escherichia coli ATCC 25922 and P. aeru-
ginosa ATCC 27853 were used for quality control of test strips. After an
incubation period of 24 h at 35 °C, MIC values were determined and evaluated
according to CLSI’s recommendation. Strains were classiﬁed into resistant (R),
intermediate resistant (I), and sensitive (S) categories.
Results and Discussion
As it was described in “Methods” section, a multistep isolation protocol was
implemented upon the experienced effectivity of the examined media. The main
steps of this selection procedure for acinetobacters are summarized in Figure 1.
The multiple, parallel checks of examined media showed that our protocol is
suitable for selective isolation of environmental Acinetobacter strains with a rate
similar to other available procedures [13], but without the addition of antibiotics,
as selective agents. The main advantage of avoidance of antibiotics during
isolation is their possible effect on the antibiotic resistance proﬁle of a given
strain; therefore, our procedure appears to be more reliable regarding antibiotic
resistance proﬁling than other methods. On the whole, this protocol can be
recommended for other researchers for further testing and adaptation to reach
a good detection rate of environmental acinetobacters with a decreasing rate of
false identiﬁcations and/or with a negative effect on antibiotic resistance proﬁling.
During our examination period, altogether 37 environmental strains belonging
to the genus Acinetobacterwere isolated with the aforementioned multistep protocol
from groundwater (26 isolates), soil (3 isolates), and surface water – ﬁshpond
Table II. The examined antibacterial agents
Antibiotic group Antibacterial agent MIC gradient (μg/ml)
Carbapenems Imipenem 0.002–32
Meropenem 0.002–32
Aminoglycosides Gentamicin 0.016–256
Fluoroquinolones Ciproﬂoxacin 0.002–32
Oﬂoxacin 0.002–32
Cephalosporins Cefotaxime 0.016–256
Ceftazidime 0.016–256
Ceftriaxone 0.016–256
Cefepime 0.016–256
Glycylcyclines Tigecycline 0.016–256
Penicillins Piperacillin 0.016–256
Rifamycins Rifampicin 0.002–32
Note: MIC: minimum inhibitory concentration.
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(8 isolates) samples (Table I). Among environmental isolates, the overwhelming
occurrence of A. calcoaceticus-related strains (n= 20) was observed followed by
representatives of species A. baumannii (n= 4), A. johnsonii (n= 4), A. pittii (n= 4),
A. beijerinckii (n= 2), Acinetobacter gyllenbergii (n= 1), Acinetobacter radio-
resistens (n= 1), and Acinetobacter soli (n= 1). Fifteen strains were isolated from
TPH-contaminated sites, 3 strains from PAH-contaminated soil, 1 strain from
MTBE-contaminated groundwater, and 18 strains from non-contaminated samples
(10 strains from groundwater and 8 strains from ﬁshponds). As we know,
Acinetobacter species can degrade different hydrocarbons [15–17, 36, 37], but
based on our results, their adaptation and degradation abilities are not determining
factors regarding their environmental frequency. About 75.6% of the identiﬁed
Acinetobacter spp. were the members of the ACB complex with veriﬁed human
health concerns and three of the remaining species (A. beijerinckii, A. johnsonii, and
A. gyllenbergii) are considered as emerging human pathogens that may become
increasingly important in the future [4].
Surprisingly, the numbers of A. baumannii strains in the examined environ-
mental samples were quite low, i.e., only 4 of 37 strains (Table I), while previous
studies reported environmental A. baumannii in greater numbers [14, 20, 21].
Figure 1. The multistep method for selective isolation and identiﬁcation of Acinetobacter strains
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However, the 16S rRNA-based identiﬁcation was missed from those papers and
identiﬁcation was based on phenotypic methods or matrix-assisted laser desorption
ionization–time of ﬂight mass spectrometry accepted with relatively low (2.005–
2.418) score values. Considering the different identiﬁcation procedures, it is possible
that the real environmental frequency of A. baumannii is lower than it was
previously expected, and our results reﬂect the proportion closer to the reality.
A. baumannii was detected mainly in ﬁshponds (three of four strains), but the low
detection rate does not let us draw general conclusions. Deﬁnite correlation between
the occurence of A. baumannii and the level or type of the contamination of
environmental samples could not be found. Further investigations may help us to
inform about the effects of the available nutrients, oxygen, or other biogeochemical
factors of the environmental samples on the frequency of A. baumannii.
The results of antibiotic susceptibility tests and the minimal inhibitory
concentrations of antibiotics in the case of the examined environmental strains are
summarized in Table III.
The results of the MIC test indicated that the majority of the investigated
environmental acinetobacters were sensitive to the most widely used antibiotics.
Imipenem, meropenem, gentamicin, ciproﬂoxacin, oﬂoxacin, and ceftazidime
proved to be highly effective antibiotics, inhibiting the growth of nearly all tested
acinetobacters (from 89% to 97%).
According to reports of National Center for Epidemiology (NCE) in Hungary,
since 2010 there has been a steady increase in the prevalence of clinical acineto-
bacters resistant to imipenem, meropenem, gentamicin, ciproﬂoxacin, and ceftazi-
dime [38]. According to NCE, 49.4% of clinical ACB complex strains exhibited
resistance to imipenem and 53% against meropenem in 2012. Approximately 20.1%
of other clinical acinetobacters (other than the members of ACB complex) showed
resistance against both tested carbapenems [39]. On the contrary, 96.5% of the
environmental strains with a closer phylogenetic relationship to the ACB complex
were susceptible to the tested carbapenems. Solely A. pittii “II HT-1/1” strain
(isolated from a ﬁshpond sample) exhibited intermediate resistance against mer-
openem. Based on the NBS Annual Reports [39], ciproﬂoxacin resistance among
clinical ACB complex strains and other clinical acinetobacters was 80.4% and
41.3% in Hungary, respectively. Conversely, 100% of our environmental ACB
complex strains showed susceptibility to ciproﬂoxacin. Although there are no
available data from 2012, in 2011, 84.5% of clinical ACB complex strains and
32.3% of other clinical acinetobacters exhibited resistance to ceftazidime [40].
In addition to the Hungarian reports of NCE, other European [41] and
American [42] study groups observed a high rate of resistance among clinical
Acinetobacter spp. to carbapenems (12% and 47%), to quinolones (51% and
67%), and to the third-generation cephalosporins (47% and 62%, respectively).
122 RADO´ ET AL.
Acta Microbiologica et Immunologica Hungarica 66, 2019
T
ab
le
II
I.
A
nt
ib
io
tic
su
sc
ep
tib
ili
ty
pa
tte
rn
s
of
th
e
is
ol
at
ed
A
ci
ne
to
ba
ct
er
st
ra
in
s
in
ve
st
ig
at
ed
w
ith
M
IC
T
es
t
S
tr
ip
s
m
et
ho
d
A
nt
ib
io
tic
re
si
st
an
ce
(R
/I
/S
),
M
IC
va
lu
es
G
ro
up
s
of
an
tim
ic
ro
bi
al
ag
en
ts
C
ar
ba
pe
ne
m
s
A
m
in
og
ly
co
si
de
s
F
lu
or
oq
ui
no
lo
ne
s
C
ep
ha
lo
sp
or
in
s
G
ly
cy
lc
yc
lin
es
P
en
ic
ill
in
s
R
if
am
yc
in
s
A
nt
im
ic
ro
bi
al
ag
en
ts
co
nc
en
tr
at
io
n
(μ
g)
IM
I
M
R
P
G
M
C
IP
O
F
X
C
T
X
C
A
Z
C
R
O
F
E
P
T
G
C
P
IP
R
D
0.
00
2–
32
0.
00
2–
32
0.
01
6–
25
6
0.
00
2–
32
0.
00
2–
32
0.
01
6–
25
6
0.
01
6–
25
6
0.
01
6–
25
6
0.
01
6–
25
6
0.
01
6–
25
6
0.
01
6–
25
6
0.
00
2–
32
A
C
B
co
m
pl
ex
A
.
ba
um
an
ni
i
S
k-
V
/3
S
0.
19
S
0.
25
S
1.
5
S
0.
19
S
0.
75
S
8
S
3
I
12
S
2
S
0.
09
4
S
16
I
3
A
.
ba
um
an
ni
i
H
T
-4
/1
S
0.
12
5
S
0.
12
5
S
0.
5
S
0.
01
2
S
0.
12
5
S
4
S
3
S
8
S
1.
5
S
<
0.
01
6
S
0.
09
4
S
0.
5
A
.
ba
um
an
ni
i
H
T
-4
/3
S
<
0.
00
2
S
0.
19
S
<
0.
01
6
S
0.
09
4
S
0.
25
S
0.
75
S
2
S
0.
75
S
2
S
0.
04
7
S
16
S
<
0.
01
6
A
.
ba
um
an
ni
i
II
H
T
-3
/1
S
0.
19
S
0.
12
5
S
0.
5
S
0.
06
4
S
0.
19
S
8
S
6
S
3
S
8
S
0.
04
7
I
24
I
3
A
.
ca
lc
oa
ce
ti
cu
s
T
N
6
S
0.
19
S
0.
25
S
1
S
0.
38
S
0.
38
I
24
S
6
I
48
I
16
S
0.
02
3
I
24
I
2
A
.
ca
lc
oa
ce
ti
cu
s
P
T
2/
2
S
0.
12
5
S
0.
38
S
1
S
0.
25
S
0.
38
I
16
S
4
I
32
S
3
S
0.
03
2
I
24
I
1.
5
A
.
ca
lc
oa
ce
ti
cu
s
P
T
3/
6
S
0.
12
5
S
0.
25
S
1.
5
S
0.
19
S
0.
25
I
12
S
4
I
24
S
4
S
0.
04
7
I
32
I
1.
5
A
.
ca
lc
oa
ce
ti
cu
s
P
T
3/
9
S
0.
12
5
S
0.
25
S
0.
38
S
0.
19
S
0.
25
S
8
S
3
I
16
S
2
S
0.
04
7
I
32
I
2
A
.
ca
lc
oa
ce
ti
cu
s
1/
2
S
0.
19
S
0.
25
S
0.
75
S
0.
09
4
S
0.
38
I
16
S
8
I
48
S
4
S
0.
03
2
I
32
I
1.
5
A
.
ca
lc
oa
ce
ti
cu
s
5/
06
/4
S
0.
12
5
S
0.
25
S
3
S
0.
19
S
0.
25
I
24
S
6
I
24
S
6
S
0.
03
2
I
48
I
1.
5
A
.
ca
lc
oa
ce
ti
cu
s
P
M
5
S
0.
19
S
0.
19
S
1
S
0.
19
S
0.
38
I
24
S
6
I
48
S
6
S
0.
04
7
R
>
25
6
I
1.
5
A
.
ca
lc
oa
ce
ti
cu
s
P
M
7
S
0.
25
S
0.
25
S
2
S
0.
19
S
0.
5
I
16
S
8
I
16
S
4
S
0.
04
7
I
64
I
3
A
.
ca
lc
oa
ce
ti
cu
s
P
M
13
S
0.
19
S
0.
38
S
0.
75
S
0.
19
S
0.
25
I
24
S
6
I
32
S
4
S
0.
03
2
R
>
25
6
I
2
A
.
ca
lc
oa
ce
ti
cu
s
P
M
7/
3
S
0.
12
5
S
0.
25
S
1
S
0.
12
5
S
0.
38
I
12
S
4
I
24
S
2
S
0.
04
7
S
16
I
1.
5
A
.
ca
lc
oa
ce
ti
cu
s
D
M
-5
/1
S
0.
5
S
0.
25
S
2
S
0.
5
S
0.
25
I
24
S
4
I
16
I
12
S
0.
09
4
I
24
I
1.
5
A
.
ca
lc
oa
ce
ti
cu
s
S
k-
V
S
0.
5
S
0.
38
S
1
S
0.
38
S
0.
19
I
16
S
6
S
12
S
8
S
0.
09
4
I
32
I
3
A
.
ca
lc
oa
ce
ti
cu
s
5/
06
S
0.
75
S
0.
38
S
1
S
0.
38
S
0.
25
I
48
S
8
I
32
I
16
S
0.
09
4
I
32
I
3
A
.
ca
lc
oa
ce
ti
cu
s
22
S
0.
5
S
0.
19
S
0.
5
S
0.
38
S
0.
19
I
12
S
4
I
16
S
8
S
0.
12
5
I
32
I
2
A
.
ca
lc
oa
ce
ti
cu
s
24
S
0.
5
S
0.
25
S
1.
5
S
0.
38
S
0.
19
I
24
S
4
I
24
S
8
S
0.
09
4
I
32
I
3
A
.
ca
lc
oa
ce
ti
cu
s
42
S
0.
75
S
0.
38
S
0.
75
S
0.
5
S
0.
25
I
32
S
8
I
16
I
12
S
0.
12
5
I
32
R
4
A
.
ca
lc
oa
ce
ti
cu
s
J5
S
0.
75
S
0.
5
S
0.
75
S
0.
5
S
0.
25
I
24
S
6
I
16
I
16
S
0.
06
4
I
32
I
3
A
.
ca
lc
oa
ce
ti
cu
s
J7
S
1
S
0.
25
S
0.
5
S
0.
75
S
1
I
32
S
4
I
24
I
12
S
0.
12
5
I
32
I
3
A
.
ca
lc
oa
ce
ti
cu
s
T
V
-1
1/
J4
S
0.
75
S
0.
38
S
1
S
0.
38
S
0.
12
5
I
32
S
8
I
16
I
16
S
0.
09
4
I
24
R
4
A
.
ca
lc
oa
ce
ti
cu
s
S
V
/1
S
1
S
0.
19
I
8
S
0.
5
S
0.
25
I
32
S
4
I
16
S
8
S
0.
06
4
I
24
I
3
A
.
pi
tt
ii
P
M
15
/3
S
0.
19
S
0.
25
S
1
S
0.
19
S
0.
25
I
12
S
2
I
12
S
2
S
0.
06
4
I
32
I
2
A
.
pi
tt
ii
II
H
T
-1
/1
S
0.
5
I
48
S
0.
12
5
S
0.
12
5
S
8
S
4
S
6
S
4
S
0.
04
7
S
0.
38
S
0.
12
5
I
3
A
.
pi
tt
ii
B
U
T
-8
/1
S
1
S
0.
38
S
0.
75
S
0.
25
S
0.
25
I
12
S
3
S
8
S
4
S
0.
12
5
I
24
I
2
A
.
pi
tt
ii
F
K
-3
/J
2
S
1
S
0.
25
S
1.
5
S
0.
25
S
0.
25
I
16
S
4
I
12
S
6
S
0.
06
4
I
24
R
4
A
.
be
ij
er
in
ck
ii
T
3N
6
R
>
32
R
>
32
S
0.
38
S
0.
75
S
0.
38
R
>
25
6
R
>
25
6
R
>
25
6
R
48
S
0.
02
3
I
24
S
0.
75
A
.
be
ij
er
in
ck
ii
Z
4N
3
S
0.
09
4
S
0.
75
S
0.
19
S
0.
12
5
S
0.
25
S
1.
5
S
3
S
4
S
1.
5
S
0.
09
4
S
12
S
0.
75
A
.
gy
ll
en
be
rg
ii
6/
2
S
0.
75
S
0.
06
4
S
0.
12
5
S
0.
38
I
4
R
12
8
R
12
8
I
24
R
32
S
0.
02
3
R
>
25
6
S
1
A
.
jo
hn
so
ni
i
Z
4S
Z
2
S
0.
12
5
S
0.
19
S
0.
5
S
0.
04
7
S
0.
19
S
6
I
12
S
3
S
8
S
<
0.
01
6
S
8
S
0.
5
A
.
jo
hn
so
ni
i
S
T
-2
S
0.
75
S
0.
38
S
0.
75
S
0.
12
5
S
0.
09
4
S
8
S
8
S
1.
5
I
16
S
0.
04
7
I
24
I
1.
5
A
.
jo
hn
so
ni
i
J6
S
0.
5
S
0.
19
S
0.
19
I
2
S
2
R
>
25
6
R
>
25
6
R
12
8
R
>
25
6
S
0.
09
4
S
6
I
1.
5
A
.
jo
hn
so
ni
i
6/
1
S
0.
5
S
0.
38
S
0.
75
R
6
S
0.
25
R
>
25
6
R
>
25
6
R
>
25
6
I
24
S
0.
02
3
R
>
25
6
S
0.
5
A
.
ra
di
or
es
is
te
ns
J3
S
3
S
0.
09
4
S
1
S
0.
09
4
S
0.
19
S
1
S
0,
5
S
1.
5
S
0.
5
S
0.
03
2
R
>
25
6
I
3
A
.
so
li
II
H
T
-4
/2
S
0.
06
4
S
0.
12
5
S
0.
25
S
0.
03
2
S
0.
38
S
3
S
1.
5
S
2
S
4
S
<
0.
01
6
R
>
25
6
I
1.
5
N
ot
e:
S
ha
de
d
ce
lls
re
pr
es
en
ta
nt
ib
io
tic
re
si
st
an
ce
.M
IC
:m
in
im
al
in
hi
bi
to
ry
co
nc
en
tr
at
io
n;
IM
I:
im
ip
en
em
;M
R
P
:m
er
op
en
em
;C
N
:g
en
ta
m
ic
in
;C
IP
:c
ip
ro
ﬂ
ox
ac
in
;O
F
X
:o
ﬂ
ox
ac
in
;
C
T
X
:
ce
fo
ta
xi
m
e;
C
A
Z
:
ce
ft
az
id
im
e;
C
R
O
:
ce
ft
ri
ax
on
e;
F
E
P
:
ce
fe
pi
m
e;
T
G
C
:
tig
ec
yc
lin
e;
P
IP
:
pi
pe
ra
ci
lli
n;
R
D
:
ri
fa
m
pi
ci
n;
S
:
se
ns
iti
ve
;
I:
in
te
rm
ed
ia
te
re
si
st
an
t;
R
:
re
si
st
an
t.
Moreover, a recent study on A. baumannii originated from a sewage treatment
plant veriﬁed that 82% of the isolates were resistant to carbapenems, ﬂuoroqui-
nolones, and colistin [14].
Until the early 1970s, gentamicin (aminoglycoside) was successfully ap-
plied against nosocomial Acinetobacter infections [42]. According to Towner [5],
acinetobacters usually show a higher rate of aminoglycoside resistance than other
pathogens, which can correlate with the results of NCE. In 2012, 69% of clinical
ACB complex strains and 34.1% of other clinical Acinetobacter strains were
resistant to gentamicin in Hungary [39], but our environmental strains showed
nearly complete susceptibility to gentamicin (97.3%).
When the aforementioned antibiotics are not effective in nosocomial
Acinetobacter-related infections, tigecycline is considered as the drug of choice
[43]. In this study, tigecycline was the sole antibiotic that inhibited the prolifera-
tion of all environmental Acinetobacter strains (100% efﬁcacy).
Cefotaxime, ceftriaxone, cefepime, piperacillin, and rifampicin were the
least effective antibiotics against the proliferation of the investigated environmen-
tal Acinetobacter strains. Acinetobacters obtained in this study widely exhibited
intermediate resistance/resistance against the tested the third-generation cepha-
losporins (70% resistance to cefotaxime, 65% to ceftriaxone, and 32.4% to
cefepime). Furthermore, 78% of strains were resistant to piperacillin and 81%
to rifampicin. The rifampicin resistance of strains presented in this study is in
contrast with the ﬁndings of Dhakephalkar and Chopade [20] who obtained
rifampicin susceptibility higher than 90% among environmental acinetobacters.
Regarding multidrug resistance, A. baumannii that usually exhibits an
elevated ability to rapidly develop antibiotic resistance [44] showed the lowest
antibiotic resistance among all tested environmental strains (susceptibility against
10–12 antibiotics) followed by A. pittii and A. calcoaceticus (susceptibility from
7 to 10 antibiotics).
Environmental strains exhibiting simultaneous resistance against several
classes of antibiotics were species A. beijerinckii, A. gyllenbergii, and A. johnsonii
that are considered as emerging human pathogens [4]. These isolates met the
currently accepted deﬁnition of multidrug resistance [45]. A. beijerinckii “T3N6”
isolated from TPH-contaminated groundwater was resistant to cephalosporins and
to the tested carbapenem, too. Since carbapenems are often considered as
antibiotics of “last resort” in treatment of MDR Acinetobacter [46], the occurrence
of a multidrug- and carbapenem-resistant environmental A. beijerinckii isolate,
whose clinical counterparts may cause endocarditis [4], can be worrying. To the
best of our knowledge, the antibiotic resistance of A. beijerinckii against carba-
penems and cephalosporins has never been reported earlier (neither among
nosocomial nor among environmental strains).
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A. johnsonii strain “6/1” (Table I) isolated from an overwintering ﬁshpond
showed the second highest rate of resistance to ﬁve antibiotics: ciproﬂoxacin,
cefotaxime, ceftazidime, ceftriaxone, and piperacillin. Therefore, strain “6/1” is
considered as MDR. A. gyllenbergii “6/2” (originated from the same ﬁshpond as
strain “6/1”) showed resistance against cephalosporins, piperacillin, and exhibited
intermediate resistance to oﬂoxacin; therefore, it is also considered as an MDR
strain. Based on the overview of scientiﬁc sources, the resistance of A. johnsonii
strains against ciproﬂoxacin, cephalosporins, and piperacillin has never been
reported earlier.
In comparison with clinical isolates, it can be summarized that the occurrence
of antibiotic resistance among terrestrial and aquatic representatives of the genus
Acinetobacter does not reach the clinical level, but it needs more attention and
continuous monitoring. The detected rates of antibiotic resistance among environ-
mental strains can be explained with several reasons such as natural resistance or
horizontal gene transfer with other naturally occurring bacteria. The antibiotic
residues in the environment and the effect of the misuse or overuse of antibiotics
may also cause problems among environmental strains. However, we did not have
the chance to examine these scenarios. Further investigations of ﬁshponds with
antibiotic treatment or communal, industrial efﬂuents with antibiotic residues may
help us to clarify this possibility. Wastewaters can be important sources of MDR
bacteria and antibiotic residues in the environment because antibiotics are not
completely metabolized by the human body [47]. Since modern wastewater
treatment plants are still not designed to remove antibiotic residues found in
domestic wastewaters [48], and urban sewage system can be considered as the
secondary habitat of A. baumannii [14], the active compounds of antibiotics in the
form of micropollutants may trigger the evolution of drug-resistant pathogens.
Regarding environmental contamination, we found that hydrocarbon-
contaminated environments (soil and groundwater) may function as reservoirs
or incubators for antibiotic-resistant acinetobacters. Considering that catabolic and
resistance genes are often located on the same mobile genetic elements (plasmids)
and a hydrocarbon pollution may act like an impulsive force for horizontal gene
transfer [49], the prevalence of MDR acinetobacters within contaminated envir-
onments is still a possibility. However, the low number of isolated ACB strains
cannot let us draw general conclusions.
Conclusions
This study provides a new, multistep method for the effective and selective
isolation of environmental Acinetobacter species, which was checked by
CARBAPENEM-RESISTANT A. BEIJERINCKII 125
Acta Microbiologica et Immunologica Hungarica 66, 2019
molecular genetic identiﬁcation based on 16S rRNA. Based on this isolation
protocol, a collection of well-characterized environmental acinetobacters was
available for further investigations.
We can conclude that environmental habitats may function as reservoirs or
incubators for acinetobacters regardless their contamination (TPH, PAH, and
MTBE) or matrix (groundwater, ﬁshpond, and soil). As their presence is veriﬁed,
the chance that environmental Acinetobacter strains can reach the infectious dose
and may pose a public health risk cannot be excluded.
The antibiotic assay served pieces of evidence for the presence of antibiotic
resistance and in some cases, multidrug resistance among the representatives of the
environmental Acinetobacter strain collection. However, the antibiotic suscepti-
bility patterns of environmental acinetobacters remarkably differ from clinical
counterparts. Tigecycline (glycylcycline) proved to be the most effective antibiotic
agent against environmental Acinetobacter proliferation (100% efﬁciency).
Based on our investigations, the detection rates and the antibiotic resistance
proﬁles of the examined Acinetobacter spp. are not worrying but cannot be
ignored and need further investigations. It is a warning sign that one MDR
organism A. beijerinckii “T3N6” was found in a TPH-contaminated groundwater,
which exhibited resistance to antibiotics of the “last resort” and its clinical
counterparts can cause life-threatening infection (endocarditis). This result sug-
gests the necessity of the detailed examination of acinetobacters that are used for
industrial purposes. As a precaution, it can be suggested that opportunistic or
unidentiﬁed microorganisms with the chance to cause infections or spread
antibiotic resistance should be replaced with safe (Risk Group 1) ones as the
classiﬁcation of 2000/54/EC Directive suggests [50].
Based on our results, environmental acinetobacters other than the members
of the clinically important ACB complex, namely A. beijerinckii, A. johnsonii, and
A. gyllenbergii require detailed examinations regarding their public health and
antibiotic resistance issues.
Our results may give a good basis for further examinations to reveal the
signiﬁcance of the human risk of environmental Acinetobacter strains. The im-
proved multistep isolation and identiﬁcation method may help to reach further
results regarding the environmental role of Acinetobacter strains of various habitats.
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